Mouse microarray could speed up cancer research

Published: 1-Oct-2005

California-based Agilent Technologies has introduced the industry\'s first commercial mouse comparative genomic hybridisation (CGH) microarray.


California-based Agilent Technologies has introduced the industry's first commercial mouse comparative genomic hybridisation (CGH) microarray.

Designed for genome-wide profiling of DNA copy number changes, the microarray 44A offers a new capability for studying genomic aberrations in cancer and other genetic diseases in this organism.

Major applications include: identifying and characterising genomic changes associated with oncogenesis and other human genetic diseases; identifying new oncogenes and tumour suppressor genes as potential therapy targets; exploring drug resistance mechanisms associated with genomic changes; and defining constitutional as well as acquired genetic changes.

'Cross-species comparison can serve as a powerful biological filter for complex onco-genomic data from human cancers,' said Lynda Chin, Associate Professor of dermatology at Dana-Farber Cancer Institute. 'The availability of this microarray offers a new level of resolution and sensitivity in the genomic analyses of mouse tumours.'

You may also like